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ABSTRACT
INTRODUCTION/BACKGROUND: The pancreatic adenocarcinoma (PA) is one of the most lethal 
malignancies being the fourth leading cause of cancer deaths worldwide. Despite the significant progress 
in diagnostic modalities the PA is still diagnosed at late stages when curative treatment is no longer 
possible. This unfavorable situation directs the clinician’s attention towards palliation and quality of life 
improvement.
MATERIALS AND METHODS: We performed a literature review of the recent developments in the area of 
palliative care for pancreatic cancer patients regarding the management of obstructive jaundice, pain and 
intestinal obstruction. The experience of our clinic with conventional surgery and nonsurgical methods is 
analysed and presented. 
OUR RESULTS: We report our experience with a group of 45 patients. One part of them received conventional 
surgical treatment, and the other one underwent endoscopic treatment. Both endoscopic stent insertion 
and surgical bypass appear to be effective treatments, but nonoperative palliation seems to be associated 
with lower complication rates, lower procedure-related mortality rates, and shorter initial periods of 
hospitalisation compared with surgical palliation. In one patient we performed recanalisation of a self-
expandable metallic stent by inserting a plastic stent into it. The jaundice was relieved successfully.
CONCLUSION: The management of PA patient remains a challenge in spite of the clear progress made in 
diagnostic studies, surgical and palliation treatments. Multidisciplinary approach is necessary to optimise 
the overall care. Considering the late diagnosis of the majority of PA patients, palliative techniques should 
not be neglected, but well mastered.
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INTRODUCTION
Pancreatic adenocarcinoma (PA) is one of the 
most fatal malignancies. Palliative care represents 
an important aspect of management in patients with 
pancreatic malignancy. In the last decades a huge 
progress was made in the diagnosis and palliative 
care of the advanced PA. Pancreatic adonocarcino-
ma is relatively common as it is the fourth leading 
cause of cancer-related mortality. The overall 5-year 
survival rate is 5%, making this disease a model tu-
mour in which to address the specialised care issues 
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of palliative medicine. A multidisciplinary approach 
to this disease is therefore recommended. 
MATERIALS AND METHODS
A review of the available literature data was 
performed. The endoscopic and surgical palliative 
procedures were analysed. We also report the clin-
ic’s experience with 45 patients for a period of 6 years 
(2006-2011). On the next table we present the most 
common symptoms of advanced pancreatic cancer.











Nausea and weight loss 50-86
The most common symptoms are the jaundice, 
abdominal pain, weight loss and diabetes.
BILIARY OBSTRUCTION - Cholestasis - usu-
ally develops in patients with a tumour in the head 
of pancreas. The obstructive jaundice could be man-
aged by endoscopic therapy as the preferred mode of 
palliation. In the past, staging laparotomy and bili-
ary bypass were frequentlyperformed for unresect-
able PC of the head. During the last decades, the de-
velopment of interventional radiology and endosco-
py has allowed palliation of obstructive jaundice by 
the insertion of percutaneous or endoluminal stents 
with minimal morbidity and mortality. Jaundice can 
cause hepatic and renal failure and can also lead to 
dysfunction of the coagulation cascade. Therefore 
treatment of obstructive jaundice is one of the major 
aims of palliative therapy for carcinomas of the pan-
creatic head. Today, the most common treatments 
are endoscopic biliary stenting and surgical biliary 
bypass surgery with or without concomitant gastro-
jejunostomy.  Biliary stenting can be done by ERCP 
(endoscopic retrograde cholangiopancreato graphy) 
or PTC (percutaneous transhepatic  Cholangiopa 
ncreatography). ERCP is an imaging technique used 
to diagnose diseases of hepatic and pancreaticobil-
iary origin. Special instruments are used to place 
stents.  The major advantage of biliary stents is that 
the procedure used to place them is minimally inva-
sive and well-tolerated by patients. 
PAIN - About 70% of patients with unresect-
able PC develop clinically important pain during 
their lives. Pain is the main cause of the significant 
drop in quality and quantity of the life of these pa-
tients and good palliation is necessary as pain inci-
dence and severity increases with disease progres-
sion. For the majority of patients, pain from PC can 
be managed with opioid analgesics. 
Abdominal and back pain are more common in 
patients with distal PC and in patients with tumors 
infiltrating peri-pancreatic nerve tissue. For the ma-
jority of PC patients, pain is still controlled pharma-
cologically even if other modalities such as:
- surgical thoracoscopic splanchnicectomy, 
- epidural anesthesia, 
- subcutaneous injection with octreotide, 
- hypofractionated-accelerated radiotherapy 
- more recently photodynamic therapy
OUR RESULTS - Over a period of 6 years, we 
retrospectively analysed the clinical records of a to-
tal of 45 patients (19 women, 28 men) with unresect-
able, histologically proven adenocarcinoma of the 
pancreatic head or distal biliary tree who presented 
for palliative therapy in our department. The median 
age of the patients included was 63 years (range: 36-
89 years). At the time of diagnosis, obstructive jaun-
dice was evident in 36 cases (76%) and these patients 
therefore required palliative treatment. Patients with 
jaundice were divided into three groups based on the 
treatment they received :
Group 1: endoscopic stent placement without 
subsequent hepaticojejunostomy;
Group 2: preoperative stenting with subsequent 
palliative hepaticojejunostomy; 
Group 3: hepaticojejunostomy without preop-
erative stenting. 
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We determined the frequency of re-hospitaliza-
tion for stent failure, stent-associated complications, 
and/or recurrent jaundice among the patients in 
Group 1. In 7 patients with obstructive jaundice, en-
doscopic stent implantation and/or surgery were im-
possible due to poor patient condition or changes in 
gastro-intestinal anatomy. In these 7 (19.5%) patients, 
the obstructive jaundice was treated radiologically by 
percutaneous transhepatic biliary drainage (PTC). 
Morbidity showed significant differences among the 
three groups: patients who only underwent stent-
ing (Group 1: 3/45, 6.38%) had a significantly low-
er morbidity rate than patients treated with preop-
erative stenting and subsequent palliative hepatico-
jejunostomy (Group 2: 8/45, 17%) while the compar-
ison between patients who underwent hepaticojeju-
nostomy without preoperative stenting did not reach 
the significant level (Group 3: 6/45, 10.6%). In Group 
1, three patients developed cholangitis or pneumo-
nia and had to be treated with antibiotics. Four pa-
tients had to have their stent changed during the ini-
tial hospital stay due to stent obstruction. The esti-
mated mean interval between initial stent placement 
and stent replacement was 69.8±30.0 days. In one pa-
tient we performed recanalisation of a self-expand-
able metallic stent by inserting a plastic stent into it. 
The jaundice was relieved successfully. Only two pa-
tients  in Group 2 showed evidence of an anastomotic 
leak after hepaticojejunostomy and preoperative bili-
ary stenting; of these two patients, one patient under-
went reoperation and the other one was treated with 
ultrasound-guided drainage. The three cases of  post-
operative wound infection which occurred in Group 
2  were all considered to be mild complications. In 
four patients who did not undergo preoperative bili-
ary stenting (Group 3), leakage occurred at the anas-
tomotic site after the hepaticojejunostomy. One of 
them underwent reoperation due to peritonitis and 
drainage failure. One patient in this group developed 
a pancreatic fistula after fine needle aspiration of the 
pancreatic tumor and one patient experienced post-
operative wound infection. None of the patients who 
underwent surgery (Groups 2 and Group 3) had to be 
re-hospitalised for recurrent jaundice. Additionally, 
gastroenterostomy (n=6; 12.8%) was only performed 
primarily in patients with evidence of duodenal ob-
struction without any increase in morbidity. In 3 pa-
tients only duodenal obstruction after hepaticojeju-
nostomy was observed and led to re-operation (gas-
troenterostomy). There were no significant differenc-
es in the mortality rates observed among the three 
patient groups (Group 1: 2.2%; Group 2: 0%; Group 
3: 2.4%; P=0.459). 
One death was attributed to cholangitis and 
subsequent sepsis and two other patients died due 
to reasons unrelated to the procedure carried out for 
their underlying disease.One patient in Group 3 died 
after hepaticojejunostomy due to leakage at the anas-
tomotic site and subsequent sepsis (2.4%). 
OVERALL SURVIVAL - Overall survival was 
significantly different among the 3 groups of pa-
tients. In particular, median overall survival was sig-
nificantly greater in patients who underwent pallia-
Scripta Scientifica Medica, vol. 46, No 1, 2014, 54-57
Copyright © Medical University of Varna   57
Nikola Kolev, Valentin Ignatov, Anton Tonev et al.
tive surgery with or without stent placement (Groups 
2 and 3: 9.0 months) than in the patients who only 
underwent stent placement (Group 1: 5.1 months). 
When the outcomes of patients in Group 1 (stent) 
were compared to those of patients in Group 2 (stent 
and hepaticojejunostomy), we found that the patients 
in Group 2 had significantly longer median survival 
(9.4 months)
CONCLUSION
Pancreatic adenocarcinoma is a model illness 
that mandates the need for good supportive and pal-
liative treatment. Pain may be linked with depression 
and anxiety. Interventional pain management tech-
nigues should not to be considered as last resort in 
pain management. Biliary obstruction can be suc-
cessfully palliated with endoscopic stent placement 
in selected patients. Multidisciplinary approach to 
this disease is therefore recommended. Due to the 
low survival rate and late diagnosis this disease is a 
model tumour in which to address the specialised 
care issues of palliative medicine.
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